JACOBS LEVY EQUITY MANAGEMENT, INC - ARBUTUS BIOPHARMA CORP ownership

ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 114 filers reported holding ARBUTUS BIOPHARMA CORP in Q4 2022. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.

Quarter-by-quarter ownership
JACOBS LEVY EQUITY MANAGEMENT, INC ownership history of ARBUTUS BIOPHARMA CORP
ValueSharesWeighting
Q3 2022$351,000
+111.4%
183,867
+230.0%
0.00%
+200.0%
Q1 2022$166,000
-23.5%
55,7130.0%0.00%0.0%
Q4 2021$217,000
+239.1%
55,713
+82.1%
0.00%0.0%
Q2 2019$64,000
-17.9%
30,593
+40.4%
0.00%0.0%
Q1 2019$78,00021,7960.00%
Other shareholders
ARBUTUS BIOPHARMA CORP shareholders Q4 2022
NameSharesValueWeighting ↓
Two Seas Capital LP 825,569$3,211,0002.46%
GREAT POINT PARTNERS LLC 668,907$2,602,0000.58%
JACOB ASSET MANAGEMENT OF NEW YORK LLC 270,000$1,050,0000.47%
QCM Cayman, Ltd. 10,205$40,0000.24%
Pitti Group Wealth Management, LLC 50,000$195,0000.22%
RTW INVESTMENTS, LP 2,504,493$9,742,0000.14%
Hudson Bay Capital Management LP 1,805,700$7,024,0000.07%
Quinn Opportunity Partners LLC 276,485$1,076,0000.07%
Kepos Capital LP 200,000$778,0000.06%
XTX Topco Ltd 29,026$113,0000.06%
View complete list of ARBUTUS BIOPHARMA CORP shareholders